Oncogenic mutations in KRAS are detected in upwards of a quarter of non-small cell lung cancers (NSCLC), and are associated with resistance to EGFR inhibitors and potentially also other chemotherapeutics [1]. Here, KRAS is linked to non-small cell lung carcinoma.